BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luo K, Gao Y, Yin S, Yao Y, Yu H, Wang G, Li J. Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer. Acta Biomater 2021;134:649-63. [PMID: 34289420 DOI: 10.1016/j.actbio.2021.07.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Jin J, Wu Y, Zhao Z, Wu Y, Zhou Y, Liu S, Sun Q, Yang G, Lin J, Nagle DG, Qin J, Zhang Z, Chen H, Zhang W, Sun S, Luan X. Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer. JCI Insight 2022;7. [DOI: 10.1172/jci.insight.160606] [Reference Citation Analysis]
2 Kandasamy G, Maity D. Current Advancements in Self-assembling Nanocarriers-Based siRNA Delivery for Cancer Therapy. Colloids and Surfaces B: Biointerfaces 2022. [DOI: 10.1016/j.colsurfb.2022.113002] [Reference Citation Analysis]
3 Gadi V, Gupta D, Shetty S. Emerging Potentials of Nanotherapeutics in Breast Cancer Microenvironment Targeting. OpenNano 2022. [DOI: 10.1016/j.onano.2022.100101] [Reference Citation Analysis]
4 Li X, Jiang W, Dong S, Li W, Zhu W, Zhou W. STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer. Biomolecules 2022;12:1450. [PMID: 36291659 DOI: 10.3390/biom12101450] [Reference Citation Analysis]
5 Deng S, Wang S, Xiao Z, Cheng D. Unprotonatable and ROS-Sensitive Nanocarrier for NIR Spatially Activated siRNA Therapy with Synergistic Drug Effect. Small 2022;:e2203823. [PMID: 36094800 DOI: 10.1002/smll.202203823] [Reference Citation Analysis]
6 Zhao Z, Zhang Y, Li C, Li X, Chu Y, Guo Q, Zhang Y, Xia W, Liu P, Chen H, Wang Y, Li C, Sun T, Jiang C. Microenvironment-tailored micelles restrain carcinoma-astrocyte crosstalk for brain metastasis. J Control Release 2022;349:520-32. [PMID: 35820539 DOI: 10.1016/j.jconrel.2022.07.009] [Reference Citation Analysis]
7 Foglizzo V, Marchiò S. Nanoparticles as Physically- and Biochemically-Tuned Drug Formulations for Cancers Therapy. Cancers (Basel) 2022;14:2473. [PMID: 35626078 DOI: 10.3390/cancers14102473] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Wang H, Man Q, Huo F, Gao X, Lin H, Li S, Wang J, Su F, Cai, L, Shi Y, Liu, B, Bu L. STAT3 pathway in cancers: Past, present, and future. MedComm 2022;3. [DOI: 10.1002/mco2.124] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
9 Hu Q, Yao J, Wang X, Wang Y, Fu X, Ma J, Lin H, Xu J, Shen L, Yu X. Combinational Chemoimmunotherapy for Breast Cancer by Codelivery of Doxorubicin and PD-L1 siRNA Using a PAMAM-Incorporated Liposomal Nanoplatform. ACS Appl Mater Interfaces 2022;14:8782-92. [PMID: 35138103 DOI: 10.1021/acsami.1c21775] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Chen Q, Xu S, Liu S, Wang Y, Liu G. Emerging nanomedicines of paclitaxel for cancer treatment. J Control Release 2022;342:280-94. [PMID: 35016919 DOI: 10.1016/j.jconrel.2022.01.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
11 Habib S, Singh M. Nucleic Acid and Drug Dual Agent Nanoplatforms for Breast Cancer. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_2] [Reference Citation Analysis]